Remove Bioethics Remove Compliance Remove FDA
article thumbnail

A Brief Quantum Medicine Policy Guide

Bill of Health

These technologies can act as privacy enhancing techniques (PET) to ensure privacy and compliance with regulations like HIPAA and GDPR. US Legal Requirements for Quantum-Powered Medical Devices In the United States, some quantum-powered medical devices may be governed under the existing FDA regulatory framework.

FDA 182
article thumbnail

A Brief Quantum Medicine Policy Guide

Bill of Health

These technologies can act as privacy enhancing techniques (PET) to ensure privacy and compliance with regulations like HIPAA and GDPR. US Legal Requirements for Quantum-Powered Medical Devices In the United States, some quantum-powered medical devices may be governed under the existing FDA regulatory framework.

FDA 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

What You Need to Know About Marijuana Rescheduling

Bill of Health

The process of rescheduling may be long and is unlikely to create a pathway to federal compliance for state-legal marijuana businesses without further federal legislation. Schedule 3 drugs must be approved by the Food and Drug Administration (FDA,) prescribed by a doctor, and distributed by a pharmacy. Victoria Litman M.Div, J.D.,

FDA 214
article thumbnail

What is a Consumer Health Company? Riffing Off of Deloitte’s Report on CHCs/A 2Q2025 Look at Self-Care Futures

Health Populi

Segment focuses that are informed by individuals’ data along with local contexts and regulatory compliance — Deloitte points to AgeTech and FemTech as examples of specific market penetration opportunities. Virtual assistants embedded with GenAI that will support consumers’ journeys, and, 5.

article thumbnail

Q&A: Alex Zhavoronkov on Cognitive Enhancement, Anti-Aging, and AI Drug Development

Bill of Health

I think that regardless of how ambitious you are, you need to play by the FDA rules and ensure complete compliance with the established clinical pathways. Our primary objective is to get these drugs approved for their intended indications first.

FDA 220